(HealthDay News) — An experimental antibody drug to help fight COVID-19 infection in immunocompromised people may be available by the end of the year.
AstraZeneca said on April 27 that its treatment, called AZD3152, appears to work in all variants to date, potentially providing necessary armor for immunocompromised people whose vaccinations have not given them enough protection, CBS News reported.
“In vitro studies demonstrated that AZD3152 neutralizes all COVID-19 variants, including Arcturus, the latest variant of concern,” Mene Pangalos, executive vice president of biopharmaceuticals at AstraZeneca, told investors on an earnings call this week.
Results of the SUPERNOVA trial on the drug could be out by September, and that may lead to an emergency use authorization by the U.S. Food and Drug Administration, CBS News reported.
AstraZeneca had previously announced promising early lab testing results for the drug. It may be helpful in the 2% of people whose immune systems are not providing effective resistance after vaccination, the company said.
AZD3152 is considered a replacement for the now-shelved Evusheld. It is based on an antibody derived from donated B cells of previously infected people, CBS News reported. It is “designed to have broader variant coverage” than Evusheld, according to the company.
Related articles:
FDA: Evusheld may be less effective against latest COVID variants (2022)
